FibroBiologics Announces Pricing of $3 Million Public Offering

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

FibroBiologics (NASDAQ: FBLG) priced a best-efforts public offering of 2,272,728 common shares and warrants at a combined price of $1.32 each, expected to raise approximately $3.0 million gross, before fees. Warrants cover up to 2,272,728 shares at a $1.32 exercise price.

The offering closing is expected on or about April 2, 2026, subject to customary conditions and stockholder approval for warrant exercises; potential additional gross proceeds from full warrant exercise equal approximately $3.0 million. Net proceeds are for working capital and general corporate purposes.

Positive

Aggregate gross proceeds of approximately $3.0 million
Potential additional gross proceeds of $3.0 million if warrants fully exercised
Exclusive placement agent engaged: H.C. Wainwright & Co.

Negative

Issuance of shares and warrants creates immediate dilution to existing shareholders
Warrants exercisable only after stockholder approval, delaying potential cash proceeds
No assurance any warrants will be exercised, limiting future funding certainty

News Market Reaction – FBLG

+0.76% 24.2x vol

59 alerts

+0.76% News Effect

-56.4% Trough in 10 hr 38 min

+$58K Valuation Impact

$7.71M Market Cap

24.2x Rel. Volume

On the day this news was published, FBLG gained 0.76%, reflecting a mild positive market reaction. Argus tracked a trough of -56.4% from its starting point during tracking. Our momentum scanner triggered 59 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $58K to the company's valuation, bringing the market cap to $7.71M at that time. Trading volume was exceptionally heavy at 24.2x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Common shares offered: 2,272,728 shares Warrants offered: 2,272,728 warrants Offering price: $1.32 per share and warrant +5 more

8 metrics

Common shares offered 2,272,728 shares Best efforts public offering

Warrants offered 2,272,728 warrants Accompanying each share or equivalent

Offering price $1.32 per share and warrant Combined public offering price

Warrant exercise price $1.32 per share Exercise price of Warrants

Gross proceeds $3 million Aggregate gross proceeds from offering

Potential warrant proceeds $3 million If all Warrants are fully exercised for cash

Warrant term 5 years Expire on five-year anniversary of Stockholder Approval

Form S-1 file number 333-294713 Registration statement for the offering

Market Reality Check

Price: $1.3300 Vol: Volume 1,011,618 is 2.13x...

high vol

$1.3300 Last Close

Volume Volume 1,011,618 is 2.13x the 20-day average of 474,318, indicating elevated pre-news activity. high

Technical Shares at $1.32 are trading well below the $8.69 200-day moving average and near the $1.265 52-week low.

Peers on Argus

FBLG fell 42.11% while momentum-screened biotech peers like CRIS, LIXT, NNVC and...

4 Up

FBLG fell 42.11% while momentum-screened biotech peers like CRIS, LIXT, NNVC and XCUR were all up roughly 4–7%, pointing to a stock-specific reaction to the offering rather than a sector-wide move.

Previous Offering Reports

5 past events · Latest: Dec 16 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 16	Offering closing	Negative	+14.5%	Closed $1.7M registered direct with matching warrants at $0.33.
Dec 15	Offering announcement	Negative	-33.1%	Announced $1.7M registered direct offering and concurrent warrants.
Nov 25	Offering closing	Negative	+1.5%	Closed $1.5M direct offering of 4.48M shares at $0.335.
Nov 24	Offering announcement	Negative	-23.5%	Announced $1.5M direct offering plus private placement warrants.
Nov 19	Offering closing	Negative	-5.8%	Closed $4.0M share and pre-funded warrant financing at $0.3303.

Pattern Detected

Financing announcements often pressured the stock, but closings sometimes saw short-term rebounds, producing a mix of aligned selloffs and divergence bounces.

Recent Company History

Historically, FibroBiologics has relied on repeated registered direct offerings with attached warrants, often via H.C. Wainwright, raising between $1.5M and $4.0M. Price reactions around these financings were mixed: some announcement days saw sharp declines, while certain closings produced modest gains. Today’s $3M best-efforts public offering with $3M in potential warrant proceeds fits this pattern of small, dilutive capital raises to fund working capital and general corporate purposes.

Historical Comparison

-9.3% avg move · Past offering-related headlines saw an average move of -9.26%. Today’s -42.11% decline ahead of a $3...

offering

-9.3%

Average Historical Move offering

Past offering-related headlines saw an average move of -9.26%. Today’s -42.11% decline ahead of a $3M stock-and-warrant deal represents a much harsher reaction than prior financings.

Financings have progressed through multiple registered direct offerings with attached five-year warrants, frequently using H.C. Wainwright as placement agent and directing proceeds to working capital and general corporate purposes.

Market Pulse Summary

This announcement details a $3M best-efforts public offering of 2,272,728 shares and matching warran...

Analysis

This announcement details a $3M best-efforts public offering of 2,272,728 shares and matching warrants at $1.32, with another $3M possible from warrant exercises. Proceeds are earmarked for working capital and general corporate purposes. Historically, FibroBiologics has used similar registered offerings to fund its fibroblast-based pipeline, with mixed share-price reactions. Investors may watch future capital needs, warrant exercises and clinical milestones to gauge ongoing dilution versus development progress.

Key Terms

best efforts public offering, warrants, exercise price, stockholder approval, +4 more

8 terms

best efforts public offering financial

"announced the pricing of a best efforts public offering of an aggregate of 2,272,728"

A best efforts public offering is a way a company sells new shares or bonds where the broker or bank agrees to try to sell as many securities as possible but does not promise to buy any unsold portion. Think of it like a salesperson taking items on consignment: they will work to sell them, but the seller bears the risk if some remain unsold. For investors, this matters because it can signal weaker demand and greater uncertainty about how many securities will actually be placed and how the price may move.

warrants financial

"and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”)"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"The Warrants will have an exercise price of $1.32 per share and will be exercisable"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

stockholder approval regulatory

"exercisable beginning on the effective date of stockholder approval of the issuance"

Stockholder approval is formal consent given by a company’s shareholders, usually through a vote at a meeting or by proxy, for major actions such as mergers, asset sales, changes to corporate structure, or amendments to governance rules. Investors pay attention because the vote can enable or block steps that materially change a company’s direction, ownership or value—like neighbors voting to allow a major renovation that would alter a building’s use and worth.

registration statement on Form S-1 regulatory

"offered pursuant to a registration statement on Form S-1 (File No. 333-294713)"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering is being made only by means of a prospectus forming part of the effective"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

placement agent financial

"H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

gross proceeds financial

"The aggregate gross proceeds to the Company from the offering are expected to be"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

AI-generated analysis. Not financial advice.

03/31/2026 - 08:00 PM

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants will have an exercise price of $1.32 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the “Stockholder Approval”) and will expire on the five-year anniversary of the date of Stockholder Approval. The closing of the offering is expected to occur on or about April 2, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Warrants, if fully exercised on a cash basis, will be approximately $3 million. No assurance can be given that any of the Warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-294713), which was declared effective by the Securities and Exchange Commission (the "SEC") on March 31, 2026. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov and a final prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About FibroBiologics, Inc.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the completion of the offering; the satisfaction of customary closing conditions related to the offering; the anticipated use of proceeds therefrom; the exercise of the Warrants prior to their expiration, and the receipt of Stockholder Approval. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) the ability of FibroBiologics to successfully prosecute its patent applications, (d) FibroBiologics’ ability to manufacture its product candidates; and (e) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Contact:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What did FibroBiologics (FBLG) announce about its April 2026 public offering?

FibroBiologics priced 2,272,728 shares plus warrants at a combined $1.32 per unit. According to the company, gross proceeds are expected to be about $3.0 million, before placement agent fees and offering expenses.

How much additional cash could FBLG receive if the warrants are exercised?

If all warrants are exercised on a cash basis, FBLG could receive about $3.0 million additional proceeds. According to the company, warrants have a $1.32 exercise price and five-year term post-approval.

When will the warrants issued in the FBLG offering become exercisable?

Warrants become exercisable beginning on the effective date of stockholder approval. According to the company, exercises will be possible only after stockholder approval and will expire five years after that date.

What will FibroBiologics use the net proceeds from the offering for?

The company intends to use net proceeds for working capital and general corporate purposes. According to the company, funds are not earmarked for a specific project in the announcement.

Who is handling placement of the FBLG offering and where is the prospectus filed?

H.C. Wainwright & Co. is the exclusive placement agent for the offering. According to the company, the registration statement was declared effective by the SEC and the prospectus is filed on the SEC website.

FibroBiologics Announces Pricing of $3 Million Public Offering